Hematology News

The subset of patients with high-risk pulmonary embolism who had hemodynamic collapse had an in-hospital mortality rate of 42%, according to a retrospective analysis of a large registry.

This year’s ASH Annual Meeting featured several high-impact abstracts.

Nearly three-quarters of individuals with sickle cell disease are not using disease-modifying therapies in their treatment, according to a study published in JAMA Network Open.

Women with venous thromboembolism associated with pregnancy, the postpartum period or combined oral contraceptives who have finished primary short-term treatment may be considered for thrombophilia testing.

In this video, Lindsey A. George, MD, discussed updated clinical trial data around hemophilia gene therapy presented at ASH Annual Meeting and Exposition.

In this video interview with Healio, Lindsey A. George, MD, spoke about a session on factor VIII biochemistry presented at ASH Annual Meeting and Exposition.

In this video, Lindsey A. George, MD, talked about improving the function of factor VIII variants for hemophilia A gene therapy, which she presented in a session at ASH Annual Meeting and Exposition.

Lindsey A. George, MD, discussed “exciting” preclinical data on gene editing for hemophilia B, which was presented in a session at ASH Annual Meeting and Exposition.

SAN DIEGO — Rilzabrutinib treatment led to rapid, stable and durable platelet responses among patients with relapsed immune thrombocytopenia, according to data presented at ASH Annual Meeting and Exposition.

Reduced-intensity haploidentical-bone marrow transplant showed durable donor engraftment at 2-years follow-up with low mortality among adults with severe sickle cell disease, according to study results.